S5 Ep49: DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
Dr. DeNunzio discusses how proton beam therapy is being used throughout oncology, the advantages of the modality and how it complements other treatment interventions, and where research with the therapy is headed.
10m Oct 11, 2021
10m
S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer
Dr. Moore discusses the basis for studying the combination of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer, data that has been generated with the combination from the phase 1/2 FRAME trial, and the potential role for the combination in clinical practice.
19m Oct 07, 2021
19m
S5 Ep47: FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.
17m Oct 04, 2021
17m
S5 Ep46: Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?
Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices
18m Sep 30, 2021
18m
S5 Ep45: Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC
Dr. Aggarwal and Dr. Girard discuss the significance of the 5-year survival data from the pivotal PACIFIC trial and the real-world benefit of the study regimen in patients with unresectable stage III NSCLC.
27m Sep 27, 2021
27m
S5 Ep44: Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer
Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.
16m Sep 23, 2021
16m
S5 Ep43: Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC
Dr. Dietrich discusses the latest developments with immunotherapy and targeted therapy in stage III non–small cell lung cancer.
16m Sep 20, 2021
16m
S5 Ep42: Neel on Maximizing Research Strides in Oncology
Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and potential future directions throughout the field.
29m Sep 16, 2021
29m
S5 Ep41: Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer
Dr. Loaiza-Bonilla discusses approaches to frontline treatment selection in metastatic pancreatic cancer, the effects of adverse effects and toxicities in treatment planning, and treatment options available to patients post gemcitabine-based regimens.
17m Sep 13, 2021
17m
S5 Ep40: Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer
Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.
17m Sep 09, 2021
17m
S5 Ep39: McKay Filters Through Frontline Treatment Considerations in mRCC
Dr. McKay discusses the importance of patient selection in advanced renal cell carcinoma, selecting between available combination regimens, and nuances regarding the timing of treatment in this disease.
17m Sep 06, 2021
17m
S5 Ep38: Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
Dr. Sosa discusses the rise in thyroid cancer cases, patient risk factors, the financial challenges associated with long-term treatment and testing, and future research directions in the field.
18m Sep 02, 2021
18m
S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS
Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.
19m Aug 30, 2021
19m
S5 Ep36: FDA Approval Insights: Nivolumab Plus Chemo for Frontline Gastric Cancer
Dr. Janjigian discusses the FDA approval of nivolumab plus chemotherapy in advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, key findings from the pivotal CheckMate-649 trial, and future directions with immunotherapy in the field.
16m Aug 26, 2021
16m
S5 Ep35: Krie and Yuan Talk Toxicity Management in Breast Cancer
Dr. Krie and Dr. Yuan discussed treatment-related adverse effects one should be aware of and prepared to manage, recommended management strategies for these TRAEs, and important points to emphasize to patients before they begin treatment.
19m Aug 23, 2021
19m
S5 Ep34: DFCI Faculty Relay Insight Into Confirmed Rebounds of Cancer Screenings After COVID-19
Dr. Labaki and Dr. Trinh discuss their research on the recovery of cancer screening tests and its link with potential racial disparities from the COVID-19 pandemic, and how the community can continue to emphasize the importance of cancer screening while working to close these disparities in cancer care.
18m Aug 19, 2021
18m
S5 Ep33: Chachoua on Leveraging Screening Opportunities in Lung Cancer
Dr. Chachoua discusses key guidelines for lung cancer screening, the psychological and financial implications of screening, and the opportunities of a screening initiative instated by NYU Langone Health.
22m Aug 16, 2021
22m
S5 Ep32: Making the Most of Molecular Testing in Breast Cancer
Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.
37m Aug 12, 2021
37m
S5 Ep31: FDA Approval Insights: Isatuximab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Dr. Moreau discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma, key findings from the pivotal IKEMA trial, and future directions with the combination.
10m Aug 09, 2021
10m
S5 Ep30: Research Reflections: Weber Relays Melanoma Updates From the 2021 ASCO Annual Meeting
Dr. Weber discusses exciting research presented during the 2021 ASCO Annual Meeting in melanoma with combination and single-agent checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and more.
21m Aug 05, 2021
21m
S5 Ep29: Rariy Reviews In-Home Infusion Initiative in Oncology
Chevon M. Rariy, MD, discusses how the implementation of telehealth during the COVID-19 pandemic shed light on the need for increased access to care for patients with cancer, as well as the potential benefits in-home infusions could offer to patients receiving chemotherapy.
18m Aug 02, 2021
18m
S5 Ep28: Understanding Actionable Pathogenic Variants Among Caribbean Patients With Breast and Ovarian Cancers
Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.
24m Jul 29, 2021
24m
S5 Ep27: Analyzing the Advancing Applications for Next-Generation Sequencing in Lung Cancer
Drs Brown and Hussain discuss the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.
25m Jul 26, 2021
25m
S5 Ep26: FDA Approval Insights: Sacituzumab Govitecan in Urothelial Cancer
Dr. Tagawa discusses the FDA approval of sacituzumab govitecan in urothelial cancer, key efficacy and safety data from the pivotal TROPHY-U-01 trial, and expectations for the confirmatory TROPiCS-04 trial.
10m Jul 22, 2021
10m
S5 Ep25: Jabbour on Tailoring Treatment With TKIs in CML and Ph+ ALL
Dr. Jabbour discusses the optimal use of ponatinib in chronic myeloid leukemia and data from the 2021 ASCO Annual Meeting with the combination of blinatumomab and ponatinib in Ph-positive acute lymphoblastic leukemia.
16m Jul 19, 2021
16m
S5 Ep24: Mayer on the Optimization of SERDs in ER+ Breast Cancer
Dr. Mayer discusses the mechanism of action of SERDs in ER-positive breast cancer, highlighted data from the AMEERA-1 trial with amcenestrant and palbociclib, and details future research efforts with SERDs.
19m Jul 15, 2021
19m
S5 Ep23: Wainberg Weighs In on Advances in HER2+ GI Cancers
In our exclusive interview, Wainberg discussed factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more!
10m Jul 12, 2021
10m
S5 Ep22: CTCA Leaders Provide Post-Pandemic Predictions in Oncology
Dr. Rariy, Ms. Brown, and Ms. Greenman discuss how the COVID-19 pandemic has led to a significant delay in cancer diagnoses, impacted the training of oncologists, and revolutionized telehealth.
26m Jul 08, 2021
26m
S5 Ep21: Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers
Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.
16m Jul 05, 2021
16m
S5 Ep20: Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer
Dr. Sherman discusses the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.
16m Jul 01, 2021
16m
S5 Ep19: Lee-Kim on Fostering a Fulfilling Fellowship in Oncology
Dr. Lee-Kim discusses her path into treating pediatric patients with cancer, key lessons that can be learned during fellowship, and tips on managing finances and burnout during a pediatric oncology fellowship program.
24m Jun 28, 2021
24m
S5 Ep18: Halmos Highlights Effort Exploring COVID-19 Vaccines in Patients With Cancer
Dr. Halmos discusses the data from a study examining seroconversion rates following COVID-19 vaccination among patients with cancer and underscores the need for novel vaccination or passive immunization strategies for immunosuppressed cohorts.
14m Jun 24, 2021
14m
S5 Ep17: Matsen Reflects on Changes to Breast Cancer Surgery During COVID-19
Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.
21m Jun 21, 2021
21m
S5 Ep16: George Gives Take on Optimal Sequencing, Strategies in Pancreatic Cancer Pipeline
Dr. George discusses treatment considerations in the first-line setting of metastatic pancreatic cancer, signs that may indicate disease progression and the need for second-line therapy, and investigational agents in the pipeline.
25m Jun 17, 2021
25m
S5 Ep15: Pant Projects an Expanding Role for Targeted Therapy in Pancreatic Cancer
Dr. Pant discusses the current role for germline and somatic testing in pancreatic cancer, examines the research landscape with PARP inhibitors, KRAS inhibitors, and other targeted agents, and shares his hope for the future of drug development in the field.
15m Jun 14, 2021
15m
S5 Ep14: Patel Previews Collaborative Research Program With SD-101 in Uveal Melanoma
Dr. Patel discusses the significance of the new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences and the resulting research evaluating the administration of an investigational toll-like receptor 9 (TLR9) agonist in combination with immunotherapy across a range of liver and pancreatic solid tumors.
12m Jun 10, 2021
12m
S5 Ep13: FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
11m Jun 07, 2021
11m
S1 Ep1: FDA Approval Insights: Tivozanib in Relapsed/Refractory Advanced RCC
Dr. Rini discusses unique elements of the TIVO-3 trial, the significance of the FDA approval of tivozanib in advanced RCC, and potential next steps for research with the TKI in the paradigm.
11m Jun 03, 2021
11m
S5 Ep12: Landgren Breaks Down the Benefit of Novel Quadruplet in Newly Diagnosed Myeloma
Dr. Landgren discusses the potential of a quadruplet regimen comprised of carfilzomib, lenalidomide, dexamethasone, and daratumumab in the treatment of patients with newly diagnosed multiple myeloma.
17m May 31, 2021
17m
S5 Ep11: Baumann Characterizes the Current Treatment Landscape of Merkel Cell Carcinoma
Dr. Baumann sheds light on the incidence, prognosis, and treatment of patients with Merkel cell carcinoma, ongoing clinical research, and strategies to raise awareness for this rare disease.
20m May 27, 2021
20m
S5 Ep10: Kaklamani Speaks to a Shifting HER2+ Breast Cancer Paradigm
In our exclusive interview, Kaklamani discussed current treatment sequencing approaches in HER2-positive breast cancer and the benefits and challenges of moving effective treatments in earlier lines of therapy.
13m May 24, 2021
13m
S5 Ep9: UCSD Faculty Contextualize Cases of Cutaneous Squamous Cell Carcinoma
In our exclusive interview, Drs Park, Daniels, Sanghvi, and Kolb, discussed two high-risk non-melanoma skin cancer cases and highlighted patient and tumor risk factors to consider in the clinical setting.
32m May 20, 2021
32m
S5 Ep8: Grivas and Wright Weigh In on the Benefits of Multidisciplinary Care in Bladder Cancer
In our exclusive interview, Drs Grivas and Wright discussed the goals of the Seattle Cancer Care Alliance Bladder Cancer Multidisciplinary Clinic, data that support the use of a multidisciplinary approach in bladder cancer, and the lingering effects of the COVID-19 pandemic on collaboration across health care specialties.
26m May 17, 2021
26m
S5 Ep7: O'Dea Offers Insight Into the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer
In our exclusive interview, O’Dea discussed the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive breast cancer, treatment sequencing recommendations, and future research directions for antibody-drug conjugates in the field.
16m May 13, 2021
16m
S5 Ep6: Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
In our exclusive interview, Dr. Federico discussed the diagnosis and presentation of neuroblastoma, the role of multidisciplinary care, and novel therapies that could significantly affect the treatment paradigm for this malignancy.
23m May 10, 2021
23m
S5 Ep5: FDA Approval Insights: Cemiplimab in Advanced PD-L1–High NSCLC and Advanced Basal Cell Carcinoma
Dr. Sezar and Dr. Stratigos discuss the FDA approvals of cemiplimab-rwlc in advanced non–small cell lung cancer and advanced basal cell carcinoma.
14m May 06, 2021
14m
S5 Ep4: FDA Approval Insights: Liso-Cel in Refractory Large B-Cell Lymphoma
Dr. Abramson discusses the significance of the FDA approval of liso-cel in refractory large B-cell lymphoma and provided insight into the efficacy and safety profiles of the CAR T-cell therapy as reported in the TRANSCEND NHL 001 trial.
10m May 03, 2021
10m
S5 Ep3: Riedel and Van Tine Spotlight Sarcoma Advances and Preview Ongoing Studies
In our exclusive interview, Riedel and Van Tine discussed the multidisciplinary management of patients with sarcoma, the clinical impact of the FDA approval of ripretinib in the gastrointestinal stromal tumor paradigm, and other exciting advances in sarcoma.
25m Apr 29, 2021
25m
S5 Ep2: FDA Approval Insights: TheraSphere Y-90 Glass Microspheres in HCC
Riad Salem, MD, discusses the unique elements of the radioembolization technology, the data that supported the regulatory approval, and the anticipated future for TheraSphere in HCC.
15m Apr 26, 2021
15m
S5 Ep1: Pagel Unpacks the Utility of PI3K Inhibitors in Lymphoid Malignancies
Dr. Pagel discusses the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.
20m Apr 22, 2021
20m